Treace Medical Concepts, Inc. announced three-year interim clinical data from its ALIGN3D?? post-market study supporting the use of the Lapiplasty®? procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons ("ACFAS") Annual Scientific Conference.

The scientific presentation, titled ?Three-Year Analyses of a Five-Year Prospective Multicenter Study Assessing Radiographic and Patient Reported Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing,? featured interim data from the prospective, five-year, multicenter ALIGN3D? clinical study with 173 enrolled patients and demonstrated positive results following the Lapiplasty® Procedure, which included: Early return to weight bearing in a walking boot at an average 8.4 days; Low radiographic recurrence rates at latest visit of 0.9% using HVA>20° (1 out of 115) and 5.2% using HVA>15° (6 out of 115); 81% reduction in pain measured using the Visual Analog Scale (?VAS?) at 24 months (n=156); 86% and 85% improvement in walking/standing and social interaction patient-reported quality of life measures, respectively, using the Manchester-Oxford Foot Questionnaire (?MOxFQ?) through latest subject visit [mean 40.5 months (n=118)]; Significant improvement in patient reported outcomes across all Patient-Reported Outcomes Measurement Information System (?PROMIS?) domains over time through latest subject visit [mean 40.5 months (n=113)]; and Low symptomatic non-union rate of 1.8% (3 out of 173).

The ALIGN3D? study is ongoing, and patients are expected to be followed for five years. The Company has submitted its primary endpoint ALIGN3D?

manuscript to a top-tier, peer-reviewed foot and ankle journal at the end of 2023 and expects publication in 2024.